Rocket Pharmaceuticals (RCKT) Announces $175M Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock
December 9, 2020 7:51 AM ESTNEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that it has commenced an underwritten public offering of $175 million of shares of its common stock. Rocket also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All the shares in the offering are to be sold by Rocket. The offering is subject to market conditions,... More
Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease
December 8, 2020 4:00 PM ESTLow Dose Showed Positive Increases in Cardiac Protein ExpressionTwo Patients With >50% by IHC, One at Month 9 and One at Month 12
Decreases in Cardiac Biomarker BNP of >50% and Stabilization of Clinical Biomarkers CK-MB and Transaminases in Two Patients
Visible Reduction of Autophagic Vacuoles, a Primary Hallmark of Danon Disease, in Heart Muscle
Individual 1.62- and 1.35-Fold Increases in Cardiac Output Observed in Two Patients at Month 12 and Month 9, Respectively
Low Dose Cohort Generally Well-Tolerated with Manageable Safety
Safety... More
